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Stroke is a devastating medical condition, killing millions of people each year and causing serious injury to many more. Despite
advances in treatment, there is still little that can be done to prevent stroke-related brain damage. The concept of neuroprotection
is a source of considerable interest in the search for novel therapies that have the potential to preserve brain tissue and improve
overall outcome. Key points of intervention have been identified inmany of the processes that are the source of damage to the brain
after stroke, and numerous treatment strategies designed to exploit them have been developed. In this review, potential targets
of neuroprotection in stroke are discussed, as well as the various treatments that have been targeted against them. In addition, a
summary of recent progress in clinical trials of neuroprotective agents in stroke is provided.
1. Introduction
Stroke is one of the leading causes of death and disability
worldwide. Despite decades of research, however, treatment
options remain limited. In ischemic stroke, the primary
focus of treatment is reperfusion. Currently, the only drug
approved for the treatment of ischemic stroke is recombinant
tissue plasminogen activator (rtPA, alteplase), which has a
limited time window for administration and increases the
risk for subsequent hemorrhage. Consequently, only a small
percentage of patients receive rtPA treatment [1]. While this
treatment is effective in opening up occluded cerebral vessels
in some patients and can lead to improved outcomes after
ischemic stroke, there are currently no approved treatments
for the myriad of damaging pathological processes that
persist in the brain long after the acute stage. These include
the processes of inflammation, excitotoxicity, oxidative stress,
apoptosis, and edema resulting from disruption of the blood-
brain barrier [2]. In hemorrhagic stroke, additional processes
include physical damage from themass of accumulated blood
itself, cytotoxicity of blood components, and vasospasm in
subarachnoid hemorrhage [3, 4].
A considerable amount of research has been invested into
the development of novel treatments capable of protecting
the brain from damage following stroke, with limited success.
Numerous neuroprotective treatments have been identified
that show great promise in animal models of stroke. Unfortu-
nately, nearly all have failed to provide protection in human
trials. The purpose of this review is to provide an overview
of targets for neuroprotection in stroke and examples of
current research on potential neuroprotective treatments.
Several reviews of neuroprotection in both ischemic and
hemorrhagic stroke have already been published in the last
few years [5–9].This paper will therefore concentrate only on
themost recent research in this field. In addition, the primary
focus will be on those treatments that have shown promise in
animal models or human patients, as opposed to those that
to date have only shown protection in vitro or in cell culture.
2. Animal Models of Stroke
A significant amount of research on neuroprotection in
stroke is performed using animal models. A large variety of
methods for inducing stroke in animals have been developed,
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and each is unique in its pathology and the effect of various
neuroprotective agents. Since the results of experiments
using a particular neuroprotective strategymay be dependent
on the specific model used, it is necessary to understand
these models and how they differ. The majority of stroke
models use rodents and can be categorized by the type
of stroke that they are designed to replicate. Models of
ischemic stroke exhibit the greatest diversity in the types
of procedures used; however most involve occlusion of one
or more blood vessels. In focal ischemia models, typically
only one vessel is occluded, the most common being middle
cerebral artery occlusion (MCAO). Global ischemia models
often involve bilateral occlusion of the common carotid
arteries (CCAO) and may also include bilateral occlusion
of another vessel such as the vertebral artery (4 vessel
models). There are also 3 vessel occlusion models that
combine bilateral common carotid occlusion with unilateral
occlusion of another vessel. Models of ischemic stroke can
also involve either permanent ischemia or transient ischemia
with subsequent reperfusion. Models of hemorrhagic stroke
typically involve the introduction of autologous blood into
the brain by direct injection or procedures that cause rupture
of a cerebral blood vessel. Other, less common stroke models
exist but will not be discussed here.More detailed discussions
of animal stroke models can be found in several reviews
[10–13].
3. Targets for Neuroprotection in Stroke
3.1. Inflammation. A significant amount of the research being
performed on neuroprotection following stroke is concen-
trated onmitigating the effects of inflammation. An overview
of the inflammatory process in the brain after stroke is shown
in Figure 1. Following ischemia and reperfusion, damaged
brain tissue secretes cytokines and chemokines that recruit
inflammatory cells to the injured area [14, 15]. These cells
release their own secretory factors, which can build up to
toxic levels. Inflammatory processes also result in the pro-
duction of reactive oxygen species, leading to oxidative stress
and activation ofmatrixmetalloproteinases (MMPs), causing
disruption of the blood-brain barrier (BBB) and edema.
On the other hand, inflammation has beneficial effects as
well, such as increasing blood flow to the affected area
and the removal of damaged tissue by phagocytic cells and
MMPs. The positive versus negative effects of inflammation
following stroke and the appropriateness of intervention are
a topic that is often debated [16]. It is generally considered,
however, that inflammation does more harm than good
after stroke, especially in the early stages. One important
molecule resulting in cell damage and death following stroke
is tumor necrosis factor alpha (TNF𝛼). TNF𝛼 interacts with
two receptors, R1 and R2, that mediate death signals via
the Fas associated death domain (FADD) and inflamma-
tion via the nuclear factor kappa-light-chain enhancer of
activated B cells (NF𝜅B), respectively [17]. Activation of
the NF𝜅B pathway is commonly used as an indicator of
inflammation in stroke studies. The interleukins are another
important set of molecules in the process of inflammation.
Interleukin-1 (IL-1) is proinflammatory, whereas IL-10 is anti-
inflammatory and IL-6 has both pro- and anti-inflammatory
effects [17]. Antagonists of the IL-1 receptor have been shown
to be neuroprotective when administered at reperfusion in
comorbid tMCAO rats [18].
As one of the early initiators of inflammation after stroke,
TNF𝛼 is an excellent target for neuroprotective treatments.
Perhaps the most straightforward way to block the effects of
TNF𝛼 is to prevent or reduce its production.The thalidomide
analog 3,6󸀠-dithiothalidomide (3,6󸀠-DT) is an inhibitor of
TNF𝛼 synthesis that has been shown to reduce the number
of activated inflammatory cells in the brain after ischemic
stroke in mice, as well as the extent of BBB disruption
[19]. Caffeic acid ester fraction reduces infarct volume and
improves performance on behavioral tests in rats subjected
to MCAO [20]. Further experiments with cultured microglia
suggest that this effect is due to inhibition of the production
of TNF𝛼, as well as nitric oxide (NO) and IL-1𝛽. Atorvastatin
suppresses TNF𝛼 levels in a rat model of intracerebral
hemorrhage, reducing brain water content and activation
of microglia [21]. Another method of action against TNF𝛼
is the use of decoy receptors. Fusion proteins consisting of
TNF receptor linked to a monoclonal antibody are capable
of crossing the blood-brain barrier and significantly reduce
infarct volumes after tMCAO in mice [22].
Activation of NF𝜅B by TNF𝛼 initiates a signaling cascade
that regulates a number of inflammatory processes, making
it a good point of intervention. Honokiol has been shown to
suppress the activation of NF𝜅B in ischemic mice as well as
levels of TNF𝛼 and significantly reduces brain water content
[23]. Rosmarinic acid blocks activation of NF𝜅B by TNF𝛼
after tMCAO in diabetic rats and reduces edema and tissue
damage [24]. Suppression of NF𝜅B activity by angiotensin-
(1–7) reduces infarct volumes, improves neurological deficits,
and decreases oxidative stress in rats subjected to pMCAO
[25]. Kaempferol glycosides inhibit the activation of NF𝜅B as
well as the signal transducer and activator of transcription
3 (STAT3), another proinflammatory transcription factor,
in tMCAO rats, resulting in reduced infarct volume and
neurological deficits [26]. It should be noted that not all
NF𝜅B activity is harmful, and harmful activation of theNF𝜅B
complex is associated with abnormal acetylation of the RelA
subunit. Using a combination of an inhibitor of one type
of deacetylase and an activator of another, it is possible
to produce a RelA acetylation similar to that seen in the
beneficial phenomenon known as ischemic preconditioning,
resulting in neuroprotection inmice exposed to tMCAO [27].
The various signaling cascades induced by stroke lead
to the activation and recruitment of inflammatory cells to
the site of injury. In the early stages of stroke, prior to
the infiltration of neutrophils and macrophages from other
locations, resident microglia are the primary inflammatory
cells in the brain. Microglia continue to be involved well
into long term recovery and have been observed 28 days
following stroke in MCAO rats [28]. Although microglia
serve a beneficial purpose by removing dead tissue, they
also release secretory factors that can accumulate to toxic
levels, particularly in cases of excess activation such as stroke.
Accordingly, treatments that limit microglial activation often
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Figure 1: Damaging inflammatory mechanisms in stroke. Proinflammatory cytokines and reactive oxygen species released by damaged
neurons lead to the activation of microglia and the expression of cellular adhesionmolecules on endothelial cells andmigrating inflammatory
cells. Infiltrating inflammatory cells and activated microglia secrete additional cytokines and oxygen species, resulting in further tissue
damage, oxidative stress, and activation of matrix metalloproteinases leading to disruption of the blood-brain barrier and edema.
have neuroprotective effects. The ginseng metabolite com-
pound K suppresses microglial activation by inhibiting mul-
tiple upstream signaling molecules and is neuroprotective in
MCAO mice [29]. Sesamin is neuroprotective in a mouse
model of ICH and has been shown to prevent an increase in
microglial cells by keeping them in their resting state [30].
Retinoids are also neuroprotective in models of ICH and
reduce levels of activated microglia even with posttreatment
[31]. Alternatively, increasing the reactivity of microglia can
also have neuroprotective effects. The ATP-dependent potas-
sium channel blocker glibenclamide increases the phagocytic
capacity ofmicroglia, resulting in improved neurological out-
come, reduced infarct volume, and enhanced neurogenesis
in rats subjected to transient or permanent MCAO [32–34].
Activation of the microglial alpha-7 nicotinic acetylcholine
receptor induces expression of the heme oxygenase-1 (HO-1)
gene, which is associated with neuroprotection in mice after
photothrombotic stroke [35].
The processes involved in inflammation may not only
directly contribute to brain damage following stroke but
may also activate secondary mechanisms that lead to further
damage. The activity of large numbers of inflammatory cells
in the affected area, combined with low oxygen and ATP
levels, leads to the formation of reactive oxygen species and
the onset of oxidative stress. Activation of MMPs, while
important for the removal of dead tissue and the ability of
immune cells to enter the brain, may also result in disruption
of the blood-brain barrier and edema due to an influx
of water. These topics will be discussed separately in the
following sections.
3.2. Oxidative Stress. The production of reactive oxygen
species (ROS) and other free radicals during stroke is a
consequence of not only inflammation but also excitotoxicity
and the inhibition of cellular respiration in a low oxygen
environment [36]. These molecules, such as hydroxyl rad-
ical, superoxide, and peroxynitrite, are highly reactive and
damaging to multiple cellular components, leading to cell
death. One way of reducing oxidative stress is to reduce
the production of free radicals. Although nitric oxide is a
normal signaling molecule in the body and has beneficial
effects in stroke, larger amounts resulting from increased
activity of the induced nitric oxide synthase (iNOS) can
lead to aberrant signaling and or react with superoxide to
produce peroxynitrite. Nebivolol decreases the expression
of iNOS following bilateral CCAO in rats and increases
expression of the beneficial endothelial nitric oxide synthase
(eNOS), leading to a reduction in histopathological changes
[37]. Another source of ROS is the nicotinamide adenine
dinucleotide phosphate (NADPH) oxidases, and inhibitors
of these enzymes could be beneficial in stroke [38]. Another
method of protection is to induce endogenous mechanisms
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for the removal of free radicals in the body. Hydrogen
sulfide gas increases the activity of superoxide dismutase
and glutathione peroxidase in rats subjected to focal cerebral
ischemia, resulting in decreased injury to neuronal mito-
chondria and a subsequent reduction inmarkers of apoptosis
[39]. Hydrogen-rich saline increases endogenous antioxidant
enzyme activity and decreases the amount of oxidative
products in pMCAO rats [40]. A nucleic acid-based product
improves the antioxidant status of neuronal mitochondria
after transient ischemia in rats [41]. Alternatively, exogenous
compounds with free radical scavenging properties can be
used.Thenovel compoundMnTm4PyPmimics the activity of
endogenous manganese superoxide dismutase, and reduces
infarct volume and neurological deficit after MCAO in mice
[42]. An extract of Ocimum sanctum protects tMCAO rats
by preserving reduced glutathione content and antioxidant
enzyme activity [43]. Hydrogen gas has been shown to
neutralize free radicals and has beneficial effects on several
contributors to early brain injury after subarachnoid hem-
orrhage in rats [44]. Furthermore, noneffective doses of the
free radical scavenger lipoic acid enhance the neuroprotective
effects of the NADPH oxidase inhibitor apocynin when
given in combination to tMCAO rats [45]. Inhibition of
downstream signaling pathways leading to oxidative stress-
induced damage, rather than the direct removal of ROS,
may also have beneficial effects. The antioxidant N-tert-
butyl-𝛼-phenylnitrone suppresses expression of complement
component 3, a mediator of inflammation that is induced by
oxidative stress, inmice after transient focal cerebral ischemia
[46].
3.3. Blood-Brain Barrier Disruption. Disruption of the blood-
brain barrier following stroke is commonly associated with
the action of two matrix metalloproteinases, MMP-2 and
MMP-9. MMP-2 is constitutively expressed at low levels in
normal brain tissue; however stroke increases its expression
and activity and also induces the expression of MMP-
9. MMP-2 cleaves and activates MMP-9, which degrades
components of the basement membrane in vascular walls
and leads to BBB disruption. Other factors involved in
BBB permeability after stroke include the extent of tight
junction formation between endothelial cells and the effects
of treatment with tissue plasminogen activator. The activity
of MMPs is regulated endogenously by the tissue inhibitor
of matrix metalloproteinase (TIMP), and treatments that
stimulate it may be of significant benefit in protection against
stroke-related brain damage. Inhibition of the expression and
activity of MMPs by other means may be protective as well.
Ethanol has been shown to inhibit the increase in MMP-
2 and MMP-9 expression after tMCAO in rats and signif-
icantly reduces brain edema [47]. Apocynum venetum leaf
extract (AVLE) also alleviates symptoms of BBB disruption
in tMCAO rats by inhibiting the expression and activity of
MMPs [48]. Hyperbaric oxygen treatment improved BBB
function in a rat embolic stroke model through modulation
of MMP-9 but displayed reduced effectiveness when admin-
istered in combination with tPA [49]. It may therefore be
of limited benefit in those stroke patients who receive tPA.
Treatments that increase the formation of tight junctionsmay
also provide neuroprotection following stroke. Doxycycline
increases the expression of tight junction proteins in tMCAO
rats and also inhibits MMPs [50]. Kruppel-like factor 2
(KLF2) protects against tMCAO in mice by regulation of
the tight junction component occluding [51]. The c-Jun N-
terminal kinase (JNK) inhibitor SP600125 restores vascular
tight junctions and alleviates BBB disruption in a ratmodel of
subarachnoid hemorrhage [52]. The GTPase RhoA is known
to play an important role in the regulation of endothelial
tight junctions, and inhibition of RhoA by fibroblast growth
factor preserves BBB integrity in a mouse model of intracere-
bral hemorrhage [53]. Additional neuroprotective strategies
include those that alleviate the negative effects of tPA. High
density lipoproteins have been shown to reduce hemorrhagic
transformation and improve BBB integrity following tPA
treatment in experimental models [54]. Neurotrophic factors
can also be used to stimulate repair mechanisms and restore
BBB function. Pigment epithelium-derived factor (PEDF),
for example, has been shown to have beneficial effects on
both BBB permeability and lesion volume after ischemia-
reperfusion in rats [55].
3.4. Excitotoxicity. During stroke, depletion of neuronal
oxygen and energy reserves leads to the release of toxic
amounts of the neurotransmitter glutamate into the extra-
cellular space [2, 17]. The subsequent activation of gluta-
mate receptors causes an influx of calcium and neuronal
depolarization, resulting in aberrant activation of numerous
calcium-dependent pathways in the brain and initiation of
the processes of necrosis, apoptosis, and autophagy. Gluta-
mate excitotoxicity therefore plays a significant role in the
pathology of stroke, and a large number of research studies
are devoted to suppressing its effects. One method of neu-
roprotection against excitotoxicity is to reduce the amount
of glutamate release during stroke. The Ginkgo biloba extract
EGb761 has been shown to significantly decrease striatal
glutamate levels inmice subjected toMCAO, accompanied by
reduced neurodegeneration and edema [56]. The individual
constituents of EGb761 also have neuroprotective properties
[57]. Another method of protection is to block the action
of glutamate receptors in the brain. The microRNA miR-
223 reduces expression of the glutamate receptor subunits
GluR2 and NR2B, and is neuroprotective against transient
global ischemia [58]. Activation of the transient receptor
potential vanilloid 4 (TRPV4) is associated with increased
activity of the NMDA receptor. HC-067047, an antagonist of
TRPV4, reduces the extent of infarct after tMCAO in mice
[59]. Magnesium sulfate is an antagonist of the N-methyl-
D-aspartate (NMDA) subtype of glutamate receptor and in
some studies has been shown to improve recovery in humans
with acute ischemic stroke [60]. On the other hand, large
scale clinical trials such as the intravenous magnesium effi-
cacy in stroke (IMAGES) trial concluded thatmagnesiumdid
not significantly improve outcome in ischemic stroke patients
but may be beneficial in lacunar stroke [61]. It is possible
that the timing of treatment is critical; therefore the field
administration of stroke therapy-magnesium (FAST-MAG)
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trial was devised to test the benefits of magnesium given
prior to arrival at a hospital. Results from a pilot trial
suggest that early administration of magnesium may have
benefits, and phase III trials are currently underway [62].
Inhibiting the influx of calcium into cells following glutamate
receptor activation can also be beneficial. Overexpression
of the transient receptor potential canonical 6 (TRPC6)
suppresses the increase in calcium induced by NMDA and
reduces infarct size and mortality in mice [63]. Hyperforin,
an activator of TRPC6, has also been found to be neuro-
protective following tMCAO in rats [64]. The compound
ginsenoside-Rd decreases expression of the calcium channel
TRPM7 in MCAO rats, which may be partially responsible
for its neuroprotective effects [65].
3.5. Apoptosis. During stroke, the diminished supply of
oxygen and glucose to the brain leads to reduced cellular
metabolism and depletion of energy stores. Combined with
tissue damage due to mechanisms such as those mentioned
above, cell death by either necrosis or apoptosis may be ini-
tiated. In the context of intervention, apoptosis is preferable
to necrosis because it can be blocked by various treatments,
allowing damaged tissue to be rescued. Cells within the
core infarct typically die by necrosis, whereas those in the
penumbra die by apoptosis. The primary factor in determin-
ing which mechanism of cell death occurs is the level of
ATP within the cell [66]. ATP is required for the process of
apoptosis, and cells with insufficient ATP stores will die by
necrosis instead. Apoptosis can occur by several pathways, as
shown in Figure 2. The mitochondrial pathway can proceed
through either caspase dependent or caspase independent
mechanisms. Alternatively, apoptosis may be induced by the
death receptor pathway.
In the caspase dependent pathway of mitochondrial
apoptosis, release of cytochromeC frommitochondria results
in activation of caspase 3, which initiates a caspase cascade
leading to the degradation of cellular components and cell
death. Caspase 3 activity is commonly used as an indicator of
apoptosis. Reduction of activated caspase 3 levels is therefore
a goal of many neuroprotective treatments. Tanshinone IIA
decreases the levels of cleaved caspase 3 in tMCAO rats,
resulting in a reduction in infarct volume, edema, and
neurological deficits. Diallyl sulfide reduces expression of
caspase 3 and increases expression of BCL-2, an endogenous
antiapoptotic protein, in tMCAO rats as well. Hypothermia
has been shown to reduce caspase 3 levels for up to 1 week
after focal cerebral ischemia in rats [67]. Pioglitazone, an
agonist of the peroxisome proliferator-activated receptor 𝛾
(PPAR𝛾), activates STAT3 in tMCAO rats, leading to changes
in the expression of antiapoptotic genes and reduced levels of
caspase 3 [68]. Caspase 3 is not the only potential therapeutic
target within this pathway, however. The cellular inhibitors
of apoptosis (cIAPs) are endogenous molecules that bind to
caspases and block their activation. Ischemic preconditioning
has been shown to increase the levels of cIAP1 in neurons
and reduce apoptosis following unilateral CCAO in rats
[69].
Although apoptosis is most commonly associated with
the caspase dependent mitochondrial pathway, other path-
ways also contribute to cell death after stroke, and neuropro-
tective agents that act upon these pathways are being inves-
tigated. The caspase independent pathway of apoptosis is
characterized bymitochondrial release of apoptosis-inducing
factor (AIF), which is stimulated by the activity of poly(ADP-
ribose) polymerase (PARP). Several treatments that inhibit
the caspase dependent pathway of apoptosis have also been
shown to inhibit the caspase independent pathway as well.
Ethanol administration decreases the expression of both
caspase 3 and AIF up to 24 hours after tMCAO in rats [70].
The nitric oxide donor (S)-ZJM-289 suppresses the release
of both cytochrome C and AIF from mitochondria and
significantly reduces injury in MCAO rats [71]. Cyclosporin
A has been shown to decrease the expression of caspase
3, AIF, and cytochrome C in a rat model of SAH [72].
Other compounds have been identified that target the caspase
independent pathway specifically. Ginsenoside-Rd has been
shown to inhibit PARP-1 activity and AIF release in rats
subjected to MCAO [73]. The death receptor pathway of
apoptosis differs from the other two in that mitochondria
are not required for its induction. Similar to the caspase
dependent pathway of mitochondrial apoptosis, however, the
death receptor pathway also uses caspase 3 as an effector.
Treatments that affect the level and activity of caspase 3 may
therefore block this pathway as well. Treatments that target
this pathway directly have also been identified. Muscone
decreases the expression of the death receptor FAS and
reduces apoptosis in MCAO rats [74]. Antibodies against
TNF𝛼, another initiator of the death receptor pathway, block
changes in the expression of caspase 3 after SAH in rats
[75].
3.6. Autophagy. The role of autophagy in stroke has only
recently begun to be elucidated and is not fully understood.
Autophagy appears to have a dual role in the response
to cellular damage, absorbing damaged components as a
protective measure in some cells and serving as a mechanism
of cell death in others. Autophagy is mediated by the ATG
family of proteins and regulated by a number of nutrient and
energy sensing pathways that converge on the mammalian
target of rapamycin (mTOR) [76, 77]. An overview of the
process of autophagy and its regulation is shown in Figure 3.
Induction of autophagy prevents cell death by apoptosis
and in this respect is considered to be beneficial. The drug
rapamycin is an inhibitor of mTOR that leads to induction
of autophagy. In a rat model of subarachnoid hemorrhage,
rapamycin suppressed apoptosis and reduced neurologi-
cal deficits, whereas inhibition of autophagy increased the
amount of brain damage [78]. Activity of the tuberous
sclerosis complex (TSC) also leads to mTOR inhibition and
induction of autophagy. Suppression of the TSC1 subunit of
this complex has been shown to increase the vulnerability
of hippocampal neurons to cell death after ischemia in vivo
[79]. Alternatively, the inhibition of autophagy can also be
neuroprotective. In pMCAO rats, ischemic postconditioning
inhibited the induction of autophagy and reduced infarct
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Figure 2: Mechanisms of induction of apoptosis. In the classical pathway, mitochondria release cytochrome C in response to cell stress and
damage, leading to activation of caspase 9 and subsequent activation of caspase 3 and other effectors of apoptosis. Alternatively, mitochondria
may also release apoptosis-inducing factor (AIF), which leads to apoptosis by a caspase independent mechanism.The death receptor pathway
involves the activation of FADDby various cell signal receptors, followed by activation of caspase 8 and the subsequent caspase cascade leading
to apoptosis.
size and edema [80]. A chemical inhibitor of autophagy
had similar effects, whereas rapamycin partially reversed
them. It is hopeful that further research will determine if
the overall effect of autophagy in stroke is beneficial or
harmful.
4. Ischemic Tolerance and the Effects of
Pre- and Postconditioning
The brain is highly susceptible to ischemia, and numerous
endogenous mechanisms exist to protect neural tissue from
its effects. Although these mechanisms are naturally stim-
ulated in response to stroke, they may also be artificially
induced by nondamaging techniques to produce a protective
state known as ischemic tolerance [81, 82]. Preconditioning
is a neuroprotective strategy by which ischemic tolerance is
induced prior to stroke in order to protect the brain from
subsequent damage and potentially could be used as a pre-
ventative measure in high risk individuals or as a precaution
against secondary stroke following medical procedures such
as aneurysm repair or cardiac surgery. In the case of naturally
occurring strokes which cannot be predicted, postcondition-
ingmay be a therapeutic strategy that could be used afterward
to accelerate or enhance protective mechanisms or as a
precaution against stroke recurrence. Preconditioning and
ischemic tolerance have already been extensively reviewed
and will only be covered briefly here [83–86]. Some evidence
suggests, however, that, although preconditioning may be
beneficial in the short term, long term structural changes
in the brain indicate that tissue damage is merely being
postponed [87]. Clinical studies are needed to test the safety
and efficacy of these novel strategies in humans.
Ischemic tolerance can be induced directly by many
conditioning mechanisms, including hypoxia/hyperoxia, hy-
pothermia/hyperthermia, drug treatments, blood vessel oc-
clusion, and dietary restriction [81]. Ischemic precondi-
tioning has been shown to downregulate components of
metabolic pathways, such as adenosine 5󸀠-monophosphate-
activated protein kinase (AMPK) [88]. Preconditioning
by the anesthetics sevoflurane and isoflurane inhibits the
expression of proapoptotic genes and upregulates anti-
apoptotic genes in MCAO rats [89]. Potential mediators
of preconditioning include the lymphocyte cell kinase
(LCK) and sodium/calcium exchangers (NCX) [90–92].
ISRN Neurology 7
Insulin receptor/IRS
InsulinCalcium
CaMKK
ATP LKB1 AMPK PI3K
DNA damage
hypoxia
stress
HIF1 REDD1 TSC1/TSC2 AKT PDK1
RHEB
mTOR/RAPTOR
ATG1/ATG13
Amino acid deprivation
Rapamycin/FKBP12
JNK
Endoplasmic reticulum stress
BCL2 ERK
ATG6/ATG14
ATG10
ATG5/ATG12/ATG16 ATG7 ATG4
LC3-II LC3-I LC3
ATG3
Induction
Isolation membrane
Nucleation
Phagophore Elongation
Autophagosome
Autolysosome
Lysosome
Fusion
Figure 3: The process of autophagy and its regulation. Induction of autophagy is inhibited by mTOR, the activity of which is controlled
by numerous upstream signaling pathways that respond to metabolic activity, energy status, and tissue damage. Progression of autophagy
requires several members of the ATG protein family, leading to the production of a membranous structure that engulfs damaged cellular
components to form the autophagosome. Subsequent fusion of the autophagosome with a lysosome results in degradation of the damaged
components. Proteins involved in the regulation of autophagy are shown in shaded boxes. Positive interactions are denoted by arrows and
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Postconditioning inhibits MMP9 expression and subsequent
degradation of the extracellular matrix in MCAO rats [93].
Ischemic tolerance in the brain can also be stimulated
remotely, for example, by application of a tourniquet to one
of the limbs. Remote preconditioning is protective in amouse
embolic stroke model, both by itself and in combination with
tissue plasminogen activator [94]. It also provides protection
by upregulation of eNOS in rats subjected to global ischemia
and reperfusion [95]. Remote preconditioning has even been
shown to have beneficial effects in human patients with
subarachnoid hemorrhage, but further studies are needed
[96].
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5. Neuroprotection in Hemorrhagic Stroke
The pathologies of ischemic and hemorrhagic stroke share
many of the same damaging processes, such as inflamma-
tion, oxidative stress, and excitotoxicity. Treatments that are
neuroprotective in one may also be beneficial in the other,
and several examples of protection in models of hemorrhagic
stroke have already been given in the previous sections.
Processes such as cytotoxicity, however, are unique to hemor-
rhagic stroke and are directly related to the accumulation of
blood in the brain. Multiple blood components are believed
to contribute to tissue damage after hemorrhage, particularly
hemoglobin. Haptoglobin and hemopexin are endogenous
proteins that bind and remove hemoglobin and its degrada-
tion products, respectively, and enhancement of their activity
may be protective [3]. Heme oxygenase (HO) is another
endogenous protein that converts heme to iron and other
products. Free iron reacts with hydrogen peroxide to form
hydroxyl radicals, leading to oxidative stress. Inhibition of
HO or chelation of iron by agents such as deferoxamine could
have beneficial effects. Valproic acid decreases the expression
of HO-1 following ICH in rats and attenuated cell death
[97]. Combination treatment of deferoxamine and statins
has been associated with improved results in behavioral tests
in rats after ICH [98]. In addition to cytotoxicity, cerebral
vasospasm is a significant contributor to death and disability
after subarachnoid hemorrhage. Because of its serious nature,
a considerable amount of research is dedicated to mitigating
its effects. Hydrogen-rich saline has been shown to decrease
vasospasm in rats after experimental SAH, possibly by
suppressing the effects of inflammation and oxidative stress
[99]. Vasospasm in SAH rats is also reduced by an analog of
𝛼-melanocyte stimulating hormone and is accompanied by
changes in the expression of factors involved in tissue damage
and repair [100].
6. Benefits of Combination Therapy for
Neuroprotection in Stroke
Thepathology of stroke is complex, withmultiple overlapping
processes leading to either damage or protection. Although
considerable neuroprotection can be gained by targeting just
one of these processes, the potential benefit is even greater
if multiple mechanisms of damage can be suppressed at the
same time. Targeting the same pathway with more than one
neuroprotective agent can also be beneficial. Consequently,
combination therapy with more than one drug has proven
to be effective in several experimental studies. The additional
benefit may be small, additive, or even synergistic in some
cases. Progesterone plus vitamin D hormone, for example,
reduces infarct size and neurological deficits in tMCAO rats
to a greater extent than either treatment alone [101]. The
combination of the anti-inflammatory properties of atorvas-
tatin and the antioxidant properties of probucol also produces
increased neuroprotection in pMCAO rats [102]. Simvastatin
combined with granulocyte colony-stimulating factor (G-
CSF) reduced recovery time in a rat model of intracerebral
hemorrhage and improved outcome [103]. Another strategy
for combination therapy is the use of one drug to block the
negative effects of another, such as tPA. Mild hypothermia,
high-density lipoproteins, activated protein C analog, and
fingolimod have all been shown to reduce the incidence of
hemorrhagic transformation following administration of tPA
in several animal models [54, 104–106].
7. Neuroprotective Treatments with
Pleiotropic Effects
Although combination therapy can produce additional ben-
efits in some cases, not all treatments are compatible with
each other. Some combinationsmay have antagonistic effects,
producing less benefit than either treatment alone. In some
cases, combination therapies may enhance damage. Fur-
thermore, combination treatment requires significantly more
testing to determine safety and effectiveness than a single
compound. There is therefore considerable interest in the
study of treatments with beneficial effects on more than
one mechanism of stroke-related damage. Some of these
treatments have only recently been discovered (Table 1) and
are still in the early stages of investigation. Others, however,
have already been the subject of considerable study and show
great promise for the treatment of stroke, as summarized
below.
7.1. Minocycline. Minocycline is a broad spectrum antibiotic
which, in addition to its antibacterial activity, also has
anti-inflammatory and antiapoptotic effects [107]. Conse-
quently, it has been shown to be protective in a number
of diseases including stroke. Minocycline is one of the
few neuroprotective agents in animal studies that has also
been proven effective in human trials. In one recent trial,
oral administration of minocycline resulted in significantly
improved outcomes as long as three months after stroke
[108]. Furthermore, animal studies indicate that additional
benefits are to be gained by combining minocycline with
other neuroprotective strategies. Minocycline reduces the
risk of subsequent hemorrhage following administration of
tissue plasminogen activator in diabetic rats subjected to
focal embolic stroke [109]. It also reduces infarct size and
suppresses several hallmarks of inflammation. Minocycline
plus normobaric hyperoxia has a synergistic effect on the
reduction in infarct volume following tMCAO in rats and
has a positive effect on hemispheric swelling that was not
seen with either treatment alone [110]. This combination
also resulted in greater inhibition of apoptosis and MMP
activation. Minocycline improves recovery after transplanta-
tion of bone marrow mononuclear cells into ischemic rats,
presumably by inhibition of microglial activation [111, 112]. It
also preconditions neural stem cells against oxidative stress,
producing reduced infarct size and improved neurological
performance following transplantation in rats exposed to
tMCAO [113].
7.2. Carnosine. Carnosine is a naturally occurring dipeptide
that has both antioxidant and antiexcitotoxic properties [114,
115]. It also is an efficient chelator of metal ions such as
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Table 1: Neuroprotective treatments with multiple beneficial effects in stroke.
Treatment Species Model Benefits Reference
ITH33/IQM9.21 Mouse Ischemia Antiexcitotoxic, antioxidant Lorrio et al. 2013 [131]
TAT-M9 Mouse Ischemia Antioxidant, antiapoptotic Guo et al. 2013 [132]
Glycyrrhizic acid Rat Ischemia Anti-inflammatory, antiexcitotoxic, and antioxidant Kim et al. 2012 [133]
Vitis amurensis extract Rat Ischemia Anti-inflammatory, antiexcitotoxic, antioxidant, and antiapoptotic Kim et al. 2012 [134]
cis-Hinokiresinols Rat Ischemia Anti-inflammatory, antioxidant Ju et al. 2013 [135]
Berberine Rat Ischemia Anti-inflammatory, antiapoptotic Zhang et al. 2012 [136]
S-Nitrosoglutathione Rat Ischemia Antioxidant, BBB integrity Khan et al. 2012 [137]
Taurine Rat Ischemia Antiexcitotoxic, antioxidant, and antiapoptotic Gharibani et al. 2013 [138]
MFG-E8 Rat Ischemia Anti-inflammatory, antiapoptotic Cheyuo et al. 2012 [139]
Nitrone derivatives Rat Ischemia Antiexcitotoxic, antioxidant Sun et al. 2012 [140]
zinc, which is required for the activity of matrix metallo-
proteinases. Preclinical studies have shown that carnosine
is well tolerated and produces robust neuroprotection in
animal models of both transient and permanent ischemia
[116]. It also readily crosses the intact blood-brain barrier,
which allows it to be administered even in the early stages
of stroke. Carnosine reduces glutamate excitotoxicity in
pMCAOmice, resulting in reduced infarct size and improved
neurologic function [117]. In another study, carnosine was
shown to decrease infarct size, MMP activity, and levels of
reactive oxygen species [118]. Carnosine can also be cleaved
by carnosinase into the amino acids alanine and histidine,
which are neuroprotective as well. Bestatin, an inhibitor of
carnosinase, increases damage in pMCAOmice [119].
7.3. Asiatic Acid. Asiatic acid is a plant-derived compound
with effects on oxidative stress, inflammation, and excitotox-
icity that has been shown to be beneficial in the treatment
of wound healing, beta-amyloid toxicity, and liver injury.
Recent evidence suggests that it may be neuroprotective in
stroke as well. In pMCAO mice, asiatic acid reduces infarct
size and improves neurologic scores, possibly by suppression
of mitochondrial damage and BBB disruption [120]. Subse-
quently, asiatic acid was also found to be neuroprotective in
multiple models of ischemia in rats by inhibiting mitochon-
drial damage and MMP-9 activation [121]. Asiatic acid also
blocks the negative effects of excitotoxicity in mice following
exposure to glutamate [122]. An extract of Centella asiatica
has been shown to improve several markers of behavioral
function and improved the antioxidant status in tMCAO rats
[123].This extract contains asiatic acid as well as several other
related compounds that also have neuroprotective properties.
Further investigation of this class of molecules is therefore
warranted to determine the extent of their effects.
7.4. Hypothermia. The beneficial effects of cooling the body
after injury are well known, and induction of hypothermia
is currently used in clinical practice to prevent secondary
brain injury after cardiac arrest and resuscitation, peri-
natal or neonatal asphyxia, and head trauma [124–126].
Considerable evidence suggests that hypothermia may be
beneficial in the treatment of stroke as well. Microarray
experiments have determined that neuroprotection result-
ing from hypothermia in MCAO rats is associated with
changes in the expression of genes involved in the processes
of inflammation, apoptosis, and calcium regulation [127].
Hypothermia induction by the neurotensin receptor 1 (NTR1)
agonist ABS-201 reduces infarct volume and suppresses cell
death by apoptosis and autophagy in mice subjected to focal
ischemia [128]. A recent meta-analysis of human clinical
trials, on the other hand, found no benefit of hypothermia
in stroke patients [129]. These trials had a limited number of
subjects, however, and larger trials are currently in progress,
for example, EuroHYP-1 and ICTuS2/3 [130].
7.5. Flavonoids. In some cases, whole classes of molecules
are known for having multiple neuroprotective effects. One
such group of compounds that are currently the subject
of intensive research are the flavonoids. These molecules
are naturally occurring compounds that readily cross the
blood-brain barrier and are well known for their protective
effects.Theflavonoids in cocoa, for example, have antioxidant
properties and also promote perfusion, angiogenesis, and
neurogenesis in the brain [141]. Xanthohumol has been
found to have anti-inflammatory, anti-apoptotic, antioxi-
dant, and antithrombotic properties. Following MCAO in
rats, xanthohumol decreases the levels of TNF𝛼, hypoxia-
inducible factor 1 alpha (HIF-1𝛼), and inducible nitric oxide
synthase (iNOS) [142]. It also reduces expression of activated
caspase 3, scavenges hydroxyl radicals, and inhibits platelet
aggregation. Treatment with naringenin results in neuropro-
tection in tMCAO rats through both antioxidant and anti-
inflammatorymechanisms [143]. Galangin improves cerebral
blood blow, inhibits apoptosis, and protects mitochondrial
function after MCAO in rats [144]. In tMCAO mice, fisetin
protects the brain against ischemic injury by suppressing
activation of cerebral inflammatory cells and inhibiting the
migration of macrophages and dendritic cells into the brain
[145]. In models of intracerebral hemorrhage, baicalin has
been found to attenuate edema of the brain and inhibit
apoptosis [146].
7.6. Cannabinoids. Another major class of molecules with
multiple beneficial effects in stroke are the cannabinoids.
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These compounds are primarily known for their anti-
inflammatory effects in many diseases including stroke [147].
Recently, however, evidence suggests that cannabinoids may
also have antioxidant and antiapoptotic effects [148]. The
cannabinoid receptor agonists WIN55,212-2 and JWH-133
reduce activation of microglia and macrophages after induc-
tion of ischemia in mice and rats, resulting in reduced infarct
size and neurological impairment, as well as protection of
oligodendrocyte precursor cells [149–151]. Another receptor
agonist, TAK-937, provides neuroprotection in tMCAO rats,
and the neuroprotective effect is increased when given in
combinationwith hypothermia [152]. Furthermore, TAK-937
not only is effective in rodent models of stroke but also has
been shown to reduce infarct volume in nonhuman primates
[153]. This specific compound is therefore of considerable
interest for future use in human trials.
8. Neuroprotective Agents in Human
Clinical Stroke Trials
Perhaps the greatest challenge in the study of neuroprotection
in stroke is the translation of animal studies to humans.
Numerous treatments that produce robust protection in
rodents have failed to provide significant benefit in clinical
trials. The various theories on the reason for this failure have
already been discussed elsewhere and will not be covered
here [5, 154, 155]. Amid the abundance of discouraging
results, however, a small number of neuroprotective strategies
have shown promise in human stroke patients. A brief
summary of recently completed clinical trials for the study
of neuroprotection in ischemic stroke and subarachnoid
hemorrhage is provided below. A discussion of recent clinical
trials for neuroprotection in intracerebral hemorrhage is
already available [8].
8.1. International Citicoline Trial on Acute Stroke (ICTUS).
Citicoline is a nutritional supplement that not only is com-
monly used to improve memory retention but also has been
shown to prevent neuronal degeneration and improve visual
function. It has already been approved in some countries
for the treatment of acute ischemic stroke. A randomized,
placebo controlled trial was conducted to evaluate the effi-
cacy of citicoline in patients with moderate to severe acute
ischemic stroke [156]. A total of 2298 patients were admin-
istered either citicoline (1000mg every 12 hours) or placebo
for up to 6 weeks. Outcome was determined at 90 days based
on the National Institute of Health Stroke Scale (NIHSS),
modified Rankin Scale (mRS), and modified Barthel Index
(mBI scores), plus the occurrence of intracranial hemorrhage,
neurologic deterioration, or death. No significant difference
in recovery was observed between the citicoline and placebo
treatment groups.
8.2. Minocycline. Minocycline is an oral antibiotic with
proven safety over years of use. In addition to its antibiotic
properties, minocycline also has anti-inflammatory and anti-
apoptotic effects that have been shown to be neuroprotective
in animal models of stroke and in previous human trials.
The efficacy of oral minocycline was examined in a
recent single-blinded open-label study [108]. Fifty patients
with acute ischemic stroke were given either minocycline
(200mg/day) or placebo for five days and assessed for various
indicators of outcome at 1, 7, 30, and 90 days. Patients
receiving minocycline showed significant improvement after
30 days in NIHSS, mBI, and mRS scores. NIHSS scores
continued to be significantly improved at 90 days. Larger
phase II and phase III trials are awaited.
8.3. Cerebrolysin. Cerebrolysin is a mixture of peptide frag-
ments that mimics the action of neurotrophic factors and
has been shown to be neuroprotective in a number of condi-
tions such as hyperthermia-induced neurotoxicity, vascular
dementia, Alzheimer’s disease, traumatic brain injury, and
stroke. A large, double-blind clinical trial was conducted to
test the efficacy and safety of Cerebrolysin in patients with
acute ischemic stroke [157]. A total of 1070 patients were
administered aspirin and either Cerebrolysin (30mL/day) or
placebo over a period of 10 days. Although no significant
difference between treatment groups was seen after 90 days, a
positive trendwas seen in those patients with anNIHSS score
greater than 12.
8.4. Ginsenoside-Rd. Ginsenoside-Rd is a calcium channel
antagonist that has been previously shown to be neuropro-
tective in human trials. An extended trial of ginsenoside-Rd
was performed in 390 patients with acute ischemic stroke
[158]. Subjects were administered ginsenoside-Rd or placebo
intravenously over a 14-day period and evaluated using
NIHSS and mRS scores for 90 days. Significant improvement
was seen with ginsenoside-Rd in NIHSS scores at 15 days and
mRS scores at 90 days.
8.5. Granulocyte-Colony Stimulating Factor (G-CSF). G-CSF
is a growth factor that stimulates the production and release
of hematopoietic stem cells in bone marrow and may be
beneficial in the enhancement of recovery after stroke. The
safety of G-CSFwas examined in a randomized phase IIb trial
[159]. A total of 60 patients with either ischemic or hemor-
rhagic stroke were given G-CSF (10 𝜇g/kg) or placebo over 5
days and monitored for the frequency of adverse effects. G-
CSF significantly increased white cell counts and produced a
trend toward reduced infarct volume. No difference was seen
between treatment groups in the frequency of adverse effects.
8.6. Evaluating Neuroprotection in Aneurysm Coiling Ther-
apy (ENACT) Trial. The compound known as NA-1 (Tat-
NR2B9c) is an inhibitor of the postsynaptic density-95 (PSD-
95) protein that is neuroprotective in primate models of
stroke. PSD-95 associates with theNMDAglutamate receptor
subtype and contributes to the process of excitotoxicity,
which is suppressed by treatment with NA-1. The safety and
efficacy of NA-1 after endovascular aneurysm repair were
examined in patients with iatrogenic stroke [160]. A total
of 185 patients were treated for a ruptured or unruptured
intracranial aneurysm by endovascular coiling, followed
by administration of NA-1 or placebo. Evaluative criteria
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included the number and size of ischemic strokes occurring
after the endovascular procedure, as well as adverse effects
associated with NA-1 treatment. NA-1 was found to decrease
the number, but not the size, of strokes occurring after
surgery. No serious adverse effects of NA-1 treatment were
observed.
8.7. Magnesium for Aneurysmal Subarachnoid Haemorrhage
(MASH-2) Trial. Magnesium is a glutamate receptor antag-
onist that has been shown to be neuroprotective due to
reduction of excitotoxicity following stroke. A multicenter
phase III trial was conducted to determine the effect of
magnesium therapy on outcome in aneurysmal subarachnoid
hemorrhage [161]. A total of 1204 patients were administered
intravenous magnesium sulfate (64mmol/day) or placebo
and evaluated for outcome on the modified Rankin Scale
for up to 90 days. No improvement in outcome was seen
with magnesium treatment versus controls. In addition, a
retrospective analysis of 2047 patients from previous trials
was also performed and similarly concluded that magnesium
has no benefit in the treatment of aneurysmal subarachnoid
hemorrhage.
8.8. Albumin in Subarachnoid Hemorrhage (ALISAH) Trial.
Albumin is an endogenous protein that has been shown
to have multiple neuroprotective effects, including antiox-
idant activity, inhibition of apoptosis, improved cellular
metabolism, and reduced edema.Amulticenter pilot trial was
conducted to evaluate the safety and tolerability of human
albumin in patients with subarachnoid hemorrhage [162]. A
total of 47 patients were tested with three different dosage
levels of human albumin, administered daily for 7 days. Albu-
min treatment was found to be well tolerated with minimal
adverse effects at doses of 625mg/kg and 1250mg/kg, but
not at higher levels. In addition, 1250mg/kg albumin trended
toward better outcome than the lower dosage level. A phase
III trial to determine the efficacy of albumin in subarachnoid
hemorrhage is currently in progress.
9. Summary
The pathology of stroke is incredibly complex, and treatment
of its devastating effects is a continuing medical challenge.
The topic of neuroprotection in stroke is equally complex,
as can be seen by the wide variety of approaches currently
being studied by the scientific community. On the one
hand, no treatment or combination of treatments can be
expected to encompass the entirety of damaging processes
that occur during stroke. In this respect, the search for better
therapies is never ending. On other hand, the availability
of a large number of neuroprotective strategies increases
the probability that one or more will ultimately prove to be
effective. This fact is particularly relevant considering that
the largemajority of neuroprotective treatments developed in
animal models have failed to produce significant benefits in
human trials. As a result, treatment options for stroke are still
limited. A few neuroprotective agents have shown promise,
however, and it is hopeful that they may be approved for
general use in the future.
The failure of preclinical studies to translate into clinical
trials highlights the importance that these studies be properly
designed. To this end, the StrokeTherapy Academic Industry
Roundtable (STAIR) has developed a set of recommendations
for the preclinical assessment of neuroprotective treatments
[163]. These include consideration of the proper animal
model, dosage level, and time points to be used, as well as the
use of physiological monitoring and more than one measure
of outcome. Recommendations for phase I/II clinical trials
of potential stroke therapies have also been developed to
facilitate the transition to phase III trials [164]. It is critical
that both preclinical studies and clinical trials be designed
to complement one another, in order to ensure that the
results are comparable and to allow subsequent investigation
of the reasons behind the success or failure of neuroprotective
treatments in humans. It has also been proposed that, rather
than proceeding directly from animal studies to clinical
trials, international multicenter preclinical studies should be
performed on promising neuroprotective agents to identify
potential problems in translating from animals to humans
[165, 166].
One complicating factor in the development of neuropro-
tective strategies is the dual nature of many of the processes
that occur in the brain during stroke. The activity of MMPs,
microglia, and other inflammatory cells, for example, can be
either damaging or protective depending on the magnitude,
location, and timing of their effects. Even mechanisms of
cell death such as apoptosis and autophagy can be beneficial
in the right circumstances. The development of potential
neuroprotective treatments, therefore, must take both the
positive and negative aspects of the stroke response into
consideration, to ensure that they are administered under the
conditions that are most appropriate and that will produce
the greatest benefit.
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